KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Travere Therapeutics (TVTX) over the last 12 years, with Q3 2025 value amounting to $5.4 million.

  • Travere Therapeutics' Other Accumulated Expenses rose 231.27% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 231.27%. This contributed to the annual value of $17.1 million for FY2024, which is 22663.74% up from last year.
  • Travere Therapeutics' Other Accumulated Expenses amounted to $5.4 million in Q3 2025, which was up 231.27% from $14.3 million recorded in Q2 2025.
  • Travere Therapeutics' Other Accumulated Expenses' 5-year high stood at $17.1 million during Q4 2024, with a 5-year trough of $5.2 million in Q3 2024.
  • Its 5-year average for Other Accumulated Expenses is $7.7 million, with a median of $5.7 million in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 4308.87% in 2022, then soared by 22663.74% in 2024.
  • Over the past 5 years, Travere Therapeutics' Other Accumulated Expenses (Quarter) stood at $6.2 million in 2021, then fell by 7.53% to $5.7 million in 2022, then fell by 8.48% to $5.2 million in 2023, then soared by 226.64% to $17.1 million in 2024, then tumbled by 68.71% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $14.3 million for Q2 2025, and $15.8 million during Q1 2025.